High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events

被引:18
|
作者
Romano, Kara D. [1 ]
Hill, Colin [1 ]
Trifiletti, Daniel M. [1 ]
Peach, M. Sean [1 ]
Horton, Bethany J. [2 ]
Shah, Neil [1 ]
Campbell, Dylan [1 ]
Libby, Bruce [1 ]
Showalter, Timothy N. [1 ]
机构
[1] Univ Virginia, Dept Radiat Oncol, Sch Med, 1240 Lee St,Box 800383, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Div Translat Res & Appl Stat, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA
关键词
IMAGE-GUIDED BRACHYTHERAPY; SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA; AMERICAN BRACHYTHERAPY; ADAPTIVE BRACHYTHERAPY; WORKING GROUP; VOLUME; DELINEATION; PARAMETERS; SURVIVAL;
D O I
10.1186/s13014-018-1074-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. Methods: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. Results: Fifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD(2)) D-2cc was >= 80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD(2) D-2cc >= 65 Gy and seven patients had a sigmoid D-2cc >= 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. Conclusions: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Dosimetric evaluation of Point A and volume-based high-dose-rate plans: a single institution study on adaptive brachytherapy planning for cervical cancer
    Paul, Arun George
    Nalichowski, Adrian
    Abrams, Judith
    Paximadis, Peter
    Zhuang, Ling
    Miller, Steven
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2018, 10 (03) : 202 - 210
  • [32] Optimization in treatment planning of high dose-rate brachytherapy - Review and analysis of mathematical models
    Moren, Bjorn
    Larsson, Torbjorn
    Tedgren, Asa Carlsson
    MEDICAL PHYSICS, 2021, 48 (05) : 2057 - 2082
  • [33] Comparative Analysis of 60Co and 192Ir Sources in High Dose Rate Brachytherapy for Cervical Cancer
    Wen, Aiping
    Wang, Xianliang
    Wang, Bingjie
    Yan, Chuanjun
    Luo, Jingyue
    Wang, Pei
    Li, Jie
    CANCERS, 2022, 14 (19)
  • [34] Severe Gastrointestinal Complications in the Era of Image-guided High-dose-rate Intracavitary Brachytherapy for Cervical Cancer
    Trifiletti, Daniel M.
    Watkins, W. Tyler
    Duska, Linda
    Libby, Bruce B.
    Showalter, Timothy N.
    CLINICAL THERAPEUTICS, 2015, 37 (01) : 49 - 60
  • [35] Treatment planning for high dose rate brachytherapy of cervical cancer based on total dose constraints
    Bahadur, Yasir A.
    Constantinescu, Camelia T.
    Hassouna, Ashraf H.
    El-Sayed, Mohamed E.
    SAUDI MEDICAL JOURNAL, 2011, 32 (05) : 495 - 503
  • [36] Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer
    Tselepidakis, Niki
    Jin, Ruyun
    Horton, Bethany
    Zheng, Wendy
    Janowski, Einsley Marie
    Romano, Kara
    BRACHYTHERAPY, 2025, 24 (03) : 389 - 394
  • [37] Dose Delivered to the Lumbosacral Plexus From High-Dose-Rate Brachytherapy for Cervical Cancer
    Rash, Dominique
    Durbin-Johnson, Blythe
    Lim, Jihoon
    Dieterich, Sonja
    Huddleston, Adam
    Yi, Sun
    Mayadev, Jyoti
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (05) : 897 - 902
  • [38] Dose to pelvic lymph nodes in locally advanced cervical cancer during high-dose-rate brachytherapy with tandem-ring applicators
    Moghani, Mona Malekzadeh
    Siavashpour, Zahra
    Ogorodniitchouk, Oleksander
    Moreno-Acosta, Pablo
    Plattard, Delphine
    Vallard, Alexis
    Sotton, Sandrine
    Bouleftour, Wafa
    Langrand-Escure, Julien
    Magne, Nicolas
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2022, 14 (02) : 183 - 188
  • [39] Comparative analysis of rectal dose parameters in image-guided high-dose-rate brachytherapy for cervical cancer with and without a rectal retractor
    Gaudet, Marc
    Lim, Peter
    Yuen, Conrad
    Zhang, Susan
    Spadinger, Ingrid
    Dubash, Rustom
    Aquino-Parsons, Christina
    BRACHYTHERAPY, 2014, 13 (03) : 257 - 262
  • [40] Effects of Interfraction Dose Variations of Target and Organs at Risk on Clinical Outcomes in High Dose Rate Brachytherapy for Cervical Cancer
    Washington, Brien
    Cheek, Dennis
    Fabian, Denise
    Kudrimoti, Mahesh
    Pokhrel, Damodar
    Wang, Chi
    Thayer-Freeman, Cameron
    Luo, Wei
    CANCERS, 2023, 15 (19)